Cagrilintide
Also known as: AM833, NN9838
A long-acting amylin analog for appetite regulation and glycemic control.
Overview
Cagrilintide is a long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It represents a new therapeutic class for obesity treatment, working through appetite suppression mechanisms distinct from GLP-1 agonists.
Mechanism of Action
Activates amylin receptors in the area postrema and hypothalamus, promoting satiety and slowing gastric emptying. Works synergistically with GLP-1 pathway when combined (CagriSema).
Pharmacokinetics
Modified for extended duration, enabling weekly dosing. Half-life approximately 7 days.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Titration
0.25 mg to 2.4 mg
Once weekly
16 weeks
Gradual dose escalation
Maintenance
2.4 mg
Once weekly
Ongoing
Target maintenance dose
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Phase 2 trials showed 10.8% weight loss as monotherapy
- 2CagriSema combination demonstrated up to 24% weight loss
- 3Additive effects when combined with semaglutide
- 4Favorable tolerability profile
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Decreased appetite
- Diarrhea
Contraindications
- Gastroparesis
- Pregnancy
Safety Considerations
GI side effects similar to amylin-based therapies. Nausea most common during titration.
Storage Requirements
Refrigerate at 2-8C
Scientific References
- 1